Authors: Muller, HJ Beier, R Loning, L Blutters-Sawatzki, R Dorffel, W Maass, E Muller-Weihrich, S Scheel-Walter, HG Scherer, F Stahnke, K Schrappe, M Horn, A Lumkemann, K Boos, J

Citation: Hj. Muller et al., Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment, BR J HAEM, 114(4), 2001, pp. 794-799

Authors: Muller, HJ Loning, L Horn, A Schwabe, D Gunkel, M Schrappe, M von Schutz, V Henze, G da Palma, JC Ritter, J Pinheiro, JPV Winkelhorst, M Boos, J

Citation: Hj. Muller et al., Pegylated asparaginase (Oncaspar (TM)) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols, BR J HAEM, 110(2), 2000, pp. 379-384

Authors: Loning, L Zimmermann, M Reiter, A Kaatsch, P Henze, G Riehm, H Schrappe, M

Citation: L. Loning et al., Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy, BLOOD, 95(9), 2000, pp. 2770-2775

Authors: Stanulla, M Loning, L Welte, K Schrappe, M

Citation: M. Stanulla et al., Secondary brain tumours in children with ALL, LANCET, 354(9184), 1999, pp. 1126-1127